Michel Gilliet

Michel Gilliet is a Full Professor at the Faculty of Biology and Medicine, University of Lausanne (UNIL), and Head of the Department of Dermatology and Venereology at the Centre Hospitalier Universitaire Vaudois (CHUV). He specializes in cutaneous immune responses and the development of immunotherapies for melanoma and other inflammatory skin diseases.

• Full Professor, Faculty of Biology and Medicine, University of Lausanne (since December 1, 2010)
• Head, Department of Dermatology and Venereology, CHUV
• Former Associate Professor and co-Director, Cancer Inflammation Center, MD Anderson Cancer Center

Education:

• MD, University of Zurich (1995)
• FMH in Dermatology, University of Zurich (2004)
• Postdoctoral Research, DNAX Research Institute, Palo Alto (1999–2001)

Michel Gilliet's research centers on the immunological mechanisms underlying skin diseases. He is particularly known for his work on antimicrobial peptides and their role in the pathogenesis of psoriasis, lupus, and other inflammatory skin conditions. His work bridges fundamental immunology and clinical applications, leading to novel immunotherapeutic strategies currently tested in clinical trials in the United States. He has contributed significantly to understanding melanoma monitoring through immunotherapy protocols.

Although specific publications are not listed in the source text, his research output is extensive and published in top-tier journals such as Nature. His editorial role as Associate Editor of the Journal of Investigative Dermatology since 2007 highlights his academic leadership. His work shows a consistent focus on translational immunodermatology, combining clinical insight with experimental discovery.

Scientific Awards:

• Recipient of multiple Swiss and international awards and distinctions

Michel Gilliet has played a key role in advancing dermatology research in Lausanne, promoting interdisciplinary collaboration and strengthening ties between academic and regional dermatologists. He established the ASTRAL registry (though this may be conflated with Patrik Michel; clarification needed), but his leadership in immunology research is well documented. He has been involved in numerous research grants and collaborative projects, particularly in cancer immunology and inflammation.

Laboratories and Research Teams:
He leads a research group focused on cutaneous immunology and immunotherapy at UNIL-CHUV, integrating clinical dermatology with experimental immunology. His team investigates immune pathways in skin cancers and autoimmune dermatoses, aiming to develop targeted therapies.